恶性黑色素瘤,转移性的临床试验
总计15316个结果
-
National Cancer Institute (NCI)完全的复发性黑色素瘤 | IV 期黑色素瘤 | IIIA期黑色素瘤 | IIIB期黑色素瘤 | IIIC期黑色素瘤 | 肢端黑色素瘤美国
-
National Cancer Institute, Naples完全的
-
EMD SeronoMerck KGaA, Darmstadt, Germany完全的N-Ras 突变的局部晚期或转移性恶性皮肤黑色素瘤美国, 瑞典, 澳大利亚, 法国, 意大利, 南非, 西班牙, 英国, 德国, 荷兰, 以色列, 新西兰, 比利时, 瑞士
-
Syndax Pharmaceuticals完全的
-
Ruhr University of Bochum完全的
-
Baylor Research Institute终止
-
Prof. Dr. med. Dirk SchadendorfBoehringer Ingelheim; medac GmbH; Alcedis GmbH完全的
-
Ruhr University of Bochum完全的
-
Centre Hospitalier Universitaire Vaudois主动,不招人
-
The Netherlands Cancer Institute4SC主动,不招人
-
Pierre Fabre Medicament招聘中
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)主动,不招人未知原发性黑色素瘤 | 病理 IIIB 期皮肤黑色素瘤 AJCC v8 | 病理学阶段 IIIC 皮肤黑色素瘤 AJCC v8 | 病理IIID期皮肤黑色素瘤AJCC v8 | 复发性皮肤黑色素瘤 | 淋巴结转移性恶性肿瘤美国
-
Dana-Farber Cancer InstituteAstraZeneca撤销
-
Pierre Fabre MedicamentBiotrial主动,不招人
-
Centre Hospitalier Universitaire de Nice招聘中
-
Centre Hospitalier Universitaire Vaudois主动,不招人
-
Providence Health & ServicesPrometheus Laboratories主动,不招人
-
H. Lee Moffitt Cancer Center and Research Institute主动,不招人
-
The Netherlands Cancer InstituteCopenhagen University Hospital at Herlev主动,不招人
-
Fondazione Melanoma OnlusClinical Research Technology S.r.l.主动,不招人
-
Canadian Cancer Trials GroupMerck Sharp & Dohme LLC终止
-
Iovance Biotherapeutics, Inc.主动,不招人
-
Novartis Pharmaceuticals终止
-
F. Stephen Hodi, MDMedImmune LLC完全的
-
The Christie NHS Foundation TrustNational Institute for Health Research, United Kingdom终止
-
Biocad主动,不招人黑色素瘤 | 黑色素瘤转移俄罗斯联邦, 白俄罗斯
-
Netherlands Working Group on Immunotherapy of OncologyHoffmann-La Roche; Amsterdam UMC, location VUmc; The Netherlands Cancer Institute终止
-
Nektar TherapeuticsImaginAb, Inc.撤销
-
OncoImmune, Inc.National Cancer Institute (NCI); Huntsman Cancer Institute撤销
-
BioNTech US Inc.Apexigen, Inc.终止
-
Nantes University HospitalUMR892完全的
-
Providence Health & ServicesProvidence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics Inc.完全的
-
Melanoma Research Foundation Breakthrough ConsortiumGenentech, Inc.终止